What was the primary driver of revenue growth in the reported periods?

Revenue growth was primarily driven by the Pharmaceutical Distribution segment, benefiting from increased prescription drug utilization and higher pharmaceutical prices. The company also saw growth from its Specialty Group, although potential future impacts from Medicare Modernization Act reimbursement changes were noted.

How did the antitrust litigation settlement impact the financial results?

The company received a $38.0 million cash settlement from a supplier in an antitrust litigation matter. This gain was recognized as a reduction of cost of goods sold, positively impacting gross profit and operating income for the quarter and nine months ended June 30, 2004.

What significant changes were made to the company's accounting policies?

The company changed its accounting policy for customer sales returns during the quarter ended June 30, 2004. Previously, returns were accounted for at the time of return; now, an accrual for estimated customer returns is recognized at the time of sale. This change reduced reported revenue and cost of goods sold by $320.4 million for the quarter and nine months ended June 30, 2004.

Are there any significant legal or regulatory matters that could impact the company?

The company is involved in various legal matters, including a stockholder derivative lawsuit, a government investigation related to a customer's illegal resale of merchandise, and pharmaceutical distribution disputes. PharMerica, a subsidiary, is facing an Office of Inspector General action related to an acquisition from 1997. While the company believes it has not engaged in wrongdoing and intends to contest these matters, their ultimate outcome is uncertain.

COR 10-Q Quarterly Report Q3 FY2004 — Revenue, Net Income, EPS

Summary

AmerisourceBergen Corporation (now Cencora, Inc.) reported solid financial results for the quarter and nine months ended June 30, 2004. The company demonstrated revenue growth driven primarily by its Pharmaceutical Distribution segment, which benefited from increased prescription drug utilization and higher pharmaceutical prices. Gross profit saw a modest increase, aided by a significant one-time gain from an antitrust litigation settlement. Despite pressures from a competitive pricing environment and changes in customer mix, the company managed to improve operating income and net income year-over-year, leading to an increase in diluted earnings per share. Management highlighted operational efficiencies and the ongoing benefits of merger integration efforts as key drivers for improved performance, particularly in reducing operating expenses as a percentage of revenue.

Key Highlights

1Total revenue increased by 6% for the quarter and 9% for the nine months ended June 30, 2004, compared to the prior year periods, primarily driven by the Pharmaceutical Distribution segment.
2A significant one-time gain of $38.0 million from an antitrust litigation settlement positively impacted gross profit.
3Operating income increased by 10% for both the quarter and nine months ended June 30, 2004, year-over-year.
4Net income rose by 12% for the quarter and 17% for the nine months ended June 30, 2004, compared to the prior year.
5Diluted earnings per share increased to $1.09 for the quarter and $3.25 for the nine months, up from $0.99 and $2.85 respectively in the prior year.
6The company continued to optimize its distribution network, with plans to consolidate facilities to enhance efficiency.
7Debt reduction efforts were evident with the redemption of subordinated notes and exchangeable subordinated debentures, leading to a reduction in interest expense.

Cencora, Inc. Quarterly Report for Q3 Ended Jun 30, 2004

Summary

Key Highlights

Frequently Asked Questions